Skip to content
TrialScanner

NCT04642638

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Phase 2/Phase 3TerminatedINOLead

Registry record

Lead sponsor
Inovio Pharmaceuticals
Conditions
Coronavirus Infection; Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); COVID-19 Disease
Primary completion
Sep 13, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04642638 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04642638: Safety, Immunogenicity, and... | TrialScanner